References
- Altekruse SF, McGlynn KA, Reichman ME (2009). Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 27, 1485-91. https://doi.org/10.1200/JCO.2008.20.7753
- Basu A, Banerjee H, Rojas H, et al (2011). Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate, 71, 755-65. https://doi.org/10.1002/pros.21292
- Breuhahn K, Gores G, Schirmacher P (2011). Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology, 53, 2112-21. https://doi.org/10.1002/hep.24313
- Dai Z, Yin J, He H, et al (2010). Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics, 10, 3789-99. https://doi.org/10.1002/pmic.200900685
- Dietz KJ, Horling F, Konig J, Baier M (2002). The function of oroplast 2-cysteine peroxiredoxin in peroxide detoxification and its regulation. J Exp Bot, 53, 1321-29. https://doi.org/10.1093/jexbot/53.372.1321
- Fu J, Qiu H, Cai M, et al (2013). Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci, 104, 508-15. https://doi.org/10.1111/cas.12100
- Huang HC, Zheng S, VanBuren V, Zhao Z (2009). Discovering disease-specific biomarker genes for cancer diagnosis and prognosis. Technol Cancer Res Treat, 9, 219-30.
- Huh JY, Kim Y, Jeong J, et al (2012). Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal, 16, 229-43. https://doi.org/10.1089/ars.2010.3766
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Ji D, Lu ZT, Li YQ, et al (2014) MACC1 expression correlates with pfkfb2 and survival in hepatocellular carcinoma. Asian Pac J Cancer Prev, 15, 999-100 https://doi.org/10.7314/APJCP.2014.15.2.999
- Jo M, Nishikawa T, Nakajima T, et al (2011). Oxidative stress is closely associated with tumor angiogenesis of hepatocellular carcinoma. J Gastroentero, 46, 809-21. https://doi.org/10.1007/s00535-011-0392-z
- Kim K, Yu M, Han S, et al (2009). Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep, 21, 1391-96.
- Kudo M. (2010) Management of hepatocellular carcinoma: from prevention to molecular targeted therapy. Oncology, 78, 1-6.
- Li XQ, Zhang SL, Cai Z, et al (2009). Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett, 275, 109-16. https://doi.org/10.1016/j.canlet.2008.10.019
- Liu L, Zhang CZ, Cai M, et al (2012). Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One, 7, 41293. https://doi.org/10.1371/journal.pone.0041293
- Liu X, Feng R, Du L (2010). The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett, 584, 3185-92. https://doi.org/10.1016/j.febslet.2010.06.002
- Mao Y, Yang H, Xu H, et al (2010). Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut, 59, 1687-93. https://doi.org/10.1136/gut.2010.214916
- Marquardt JU, Galle PR, Teufel A (2012). [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy]. Dtsch Med Wochenschr, 137, 855-60. https://doi.org/10.1055/s-0032-1304843
- Marra M, Sordelli IM, Lombardi A, et al (2011). Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med, 9, 171. https://doi.org/10.1186/1479-5876-9-171
- Nagasue N (1998). Liver resection for hepatocellular carcinoma: indications, techniques, complications, and prognostic factors. J Hepatobiliary Pancreat Surg, 5, 7-13. https://doi.org/10.1007/PL00009954
- Pateron D, Ganne N, Trinchet JC, et al (1994). Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol, 20, 65-71. https://doi.org/10.1016/S0168-8278(05)80468-4
- Qiao B, Wang J, Xie J, et al (2012). Detection and identification of by a proteomic approach. Int J Mol Med, 29, 832-40.
- Rabilloud T, Heller M, Gasnier F, et al (2002). Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem, 277, 19396-401. https://doi.org/10.1074/jbc.M106585200
- Shariff MI, Cox IJ, Gomaa AI, et al (2009). Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol, 3, 353-67. https://doi.org/10.1586/egh.09.35
- Shen Q, Fan J, Yang XR, et al (2012). Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol, 13, 817-26. https://doi.org/10.1016/S1470-2045(12)70233-4
- Song IS, Kim HK, Jeong SH, et al (2011). Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci, 12, 7163-85 https://doi.org/10.3390/ijms12107163
- Trachootham D, Alexandre J, Huang P. (2009). Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 8, 579-91. https://doi.org/10.1038/nrd2803
- Wonsey DR, Zeller KI, Dang CV (2002). The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA, 99, 6649-54. https://doi.org/10.1073/pnas.102523299
- Wu XY, Fu ZX, Wang XH (2010). Peroxiredoxins in colorectal neoplasms. Histol Histopathol, 25, 1297-303.
- Yamamoto K, Imamura H, Matsuyama Y, et al (2010). AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC. J Gastroenterol, 45, 1272-82. https://doi.org/10.1007/s00535-010-0278-5
Cited by
- Differential Expression of IQGAP1/2 in Hepatocellular Carcinoma and its Relationship with Clinical Outcomes vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4951
- Elevated PIVKA-II is Associated with Early Recurrence and Poor Prognosis in BCLC 0-A Hepatocellular Carcinomas vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6673
- Plasma Nuclear Factor Kappa B and Serum Peroxiredoxin 3 in Early Diagnosis of Hepatocellular Carcinoma vol.16, pp.4, 2015, https://doi.org/10.7314/APJCP.2015.16.4.1657
- Inhibits Growth and Promotes Invasion and Extracellular Matrix Degradation in Hepatocellular Carcinoma Cells vol.15, pp.5, 2016, https://doi.org/10.1021/acs.jproteome.5b01125
- Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review) vol.36, pp.2, 2016, https://doi.org/10.3892/or.2016.4842
- Epigenetic regulation of peroxiredoxins: Implications in the pathogenesis of cancer vol.242, pp.2, 2017, https://doi.org/10.1177/1535370216669834
- Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantation vol.14, pp.2, 2017, https://doi.org/10.3892/ol.2017.6333
- The prognostic values of the peroxiredoxins family in ovarian cancer vol.38, pp.5, 2018, https://doi.org/10.1042/BSR20180667